|
Title
|
|
|
|
Prophylactic azithromycin therapy after lung transplantation : post hoc analysis of a randomized controlled trial
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obliterans syndrome (BOS) 2 years after lung transplantation (LTx). In the current study, we re-evaluated the long-term effects of this prophylactic approach in view of the updated classification system for chronic lung allograft dysfunction (CLAD). A retrospective, intention-to-treat analysis of a randomized controlled trial comparing prophylactic treatment with placebo (n = 43) versus azithromycin (n = 40) after LTx was performed. Graft dysfunction (CLAD), graft loss (retransplantation, mortality), evolution of pulmonary function and functional exercise capacity were analyzed 7 years after inclusion of the last study subject. Following LTx, 22/43 (51%) patients of the placebo group and 11/40 (28%) patients of the azithromycin group ever developed CLAD (p = 0.043). CLAD-free survival was significantly longer in the azithromycin group (p = 0.024). No difference was present in proportion of obstructive versus restrictive CLAD between both groups. Graft loss was similar in both groups: 23/43 (53%) versus 16/40 (40%) patients (p = 0.27). Long-term pulmonary function and functional exercise capacity were significantly better in the azithromycin group (p < 0.05). Prophylactic azithromycin therapy reduces long-term CLAD prevalence and improves CLAD-free survival, pulmonary function, and functional exercise capacity after LTx. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
American journal of transplantation. - Copenhagen
| |
|
Publication
|
|
|
|
Copenhagen
:
2016
| |
|
ISSN
|
|
|
|
1600-6135
| |
|
DOI
|
|
|
|
10.1111/AJT.13417
| |
|
Volume/pages
|
|
|
|
16
:1
(2016)
, p. 254-261
| |
|
ISI
|
|
|
|
000368507300029
| |
|
Pubmed ID
|
|
|
|
26372728
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|